| PD-1 blockade in tumors with mismatch-repair deficiency DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ... New England Journal of Medicine 372 (26), 2509-2520, 2015 | 9452 | 2015 |
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 5993 | 2017 |
| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 4680 | 2014 |
| Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ... Journal of Clinical Oncology 38 (1), 1, 2020 | 2180 | 2020 |
| Pembrolizumab in microsatellite-instability–high advanced colorectal cancer T André, KK Shiu, TW Kim, BV Jensen, LH Jensen, C Punt, D Smith, ... New England Journal of Medicine 383 (23), 2207-2218, 2020 | 1883 | 2020 |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ... The Lancet Oncology 17 (7), 883-895, 2016 | 1290 | 2016 |
| Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... Cancer discovery 7 (2), 188-201, 2017 | 1161 | 2017 |
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial K Muro, HC Chung, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, ... The lancet oncology 17 (6), 717-726, 2016 | 1125 | 2016 |
| Microsatellite instability as a biomarker for PD-1 blockade JC Dudley, MT Lin, DT Le, JR Eshleman Clinical Cancer Research 22 (4), 813-820, 2016 | 856 | 2016 |
| Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164 DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ... Journal of Clinical Oncology 38 (1), 11, 2020 | 784 | 2020 |
| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ... The lancet oncology 17 (11), 1590-1598, 2016 | 726 | 2016 |
| Evolutionary dynamics of cancer in response to targeted combination therapy I Bozic, JG Reiter, B Allen, T Antal, K Chatterjee, P Shah, YS Moon, ... elife 2, e00747, 2013 | 681 | 2013 |
| Safety and survival with GVAX pancreas prime and Listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer DT Le, A Wang-Gillam, V Picozzi, TF Greten, T Crocenzi, G Springett, ... Journal of clinical Oncology 33 (12), 1325, 2015 | 634 | 2015 |
| Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors FB Cortazar, KA Marrone, ML Troxell, KM Ralto, MP Hoenig, JR Brahmer, ... Kidney international 90 (3), 638-647, 2016 | 604 | 2016 |
| Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer DT Le, E Lutz, JN Uram, EA Sugar, B Onners, S Solt, L Zheng, LA Diaz Jr, ... Journal of immunotherapy 36 (7), 382-389, 2013 | 586 | 2013 |
| CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto, P Sharma, PA Ott, ... Journal of Clinical Oncology 36 (28), 2836, 2018 | 572 | 2018 |
| Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ... Science 364 (6439), 485-491, 2019 | 439 | 2019 |
| DNA mismatch repair in cancer M Baretti, DT Le Pharmacology & therapeutics 189, 45-62, 2018 | 435 | 2018 |
| A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy … L Eric, CJ Yeo, KD Lillemoe, B Biedrzycki, B Kobrin, J Herman, E Sugar, ... Annals of surgery 253 (2), 328-335, 2011 | 430 | 2011 |
| Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat JD Jentsch, A Tran, D Le, KD Youngren, RH Roth Neuropsychopharmacology 17 (2), 92-99, 1997 | 385 | 1997 |
